Description
Rilonacept (Arcalyst) is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the Fc portion of human IgG1. Rilonacept (Arcalyst) blocks IL-1b signaling by acting as a soluble decoy receptor that binds IL-1b and prevents its interaction with cell surface receptors. Rilonacept (Arcalyst) also binds IL-1 and IL-1 receptor antagonist (IL-1ra) with reduced affinity.
Canakinumab (Ilaris
(R)
) is a recombinant, human anti-human-IL-1b monoclonal antibody that belongs to the IgG1/K isotype subclass. Canakinumab (Ilaris) binds to human IL-1b and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1a or IL-1 receptor antagonist (IL-1ra).
Note:
Canakinumab (Ilaris) may be covered under the medical benefit. Rilonacept (Arcalyst) may be covered under the pharmacy benefit.
